Abstract: Bone has always been regarded as a merely structural tissue, a "hard" scaffold protecting all of its "soft" fellows, while they did the rest of the work. In the last few decades this concept has totally changed, and new findings are starting to portray bone as a very talkative tissue that is capable not only of being regulated, but also of regulating other organs. In this review we aim to discuss the endocrine regulation that bone has over whole-body homeostasis, with emphasis on energy metabolism, male fertility, cognitive functions and phosphate (Pi) metabolism. These delicate tasks are mainly carried out by two known hormones, osteocalcin (Ocn) and fibroblast growth factor 23 (FGF23) and possibly other hormones that are yet to be found. The extreme plasticity and dynamicity of bone allows a very fine tuning over the actions these hormones exert, portraying this tissue as a full-fledged endocrine organ, in addition to its classical roles. In conclusion, our findings suggest that bone also has a "soft side", and is daily taking care of our entire organism in ways that were unknown until the last few years.
Introduction
Every anatomy textbook describes the skeletal system as the hard scaffold sustaining all of our soft organs, and the roles of the bone have always been thought to be very simple: movement, protection and calcium homeostasis.
Our long bones are connected to muscles by tendons, and movement would be impossible without them. Our vertebrae protect our spinal cord, our rib cage shields our heart, lungs and thymus, bone marrow is hosted inside cavities of all endochondral bones and our brain is kept safe inside the cranium. All of these examples illustrate a "hard" tissue protecting its "soft" fellows, while they take care of all the interesting work in our organism. But is it really so?
In this review we mean to state that bone also has a "soft soul", communicating with distant organs and participating in whole body homeostasis in ways that were not known until the last few years.
In this review, we will first provide a brief overview of the biology and physiology of bone, a connective tissue that has the peculiarity of having a mineralized matrix which, however, does not hamper its plasticity. Another peculiarity is the high versatility of bone cells, which not only contribute to bone homeostasis but interact and influence each other and accomplish many other unsuspected functions. This description portrays bone as a pivotal tissue in whole bone homeostasis, capable of regulating several other tissues and of being in turn influenced by them.
Biology of the bone
Like all connective tissues, bone consists of two main components: an extracellular matrix, composed of an organic and an inorganic component, and a cell component. The organic part is mainly represented by collagen I fibers and an amorphous substance, consisting of noncollagenous glycoproteins and proteoglycans. The inorganic part is composed of calcium and phosphate (Pi) carbonate, which are mainly organized as hydroxyapatite crystals. The cells of bone can be classified into three different types: osteoclasts, osteoblasts and osteocytes. Even though these cells have different origins and functions, they interact with each other in a concerted and organized manner to guarantee a correct homeostasis of bone. In the next section we will describe the main features of these cells.
Osteoclasts: the bone-hungry cells
Osteoclasts are multinucleate giant cells generated from precursors belonging to the colony forming unitmacrophage (CFU-M) lineage. One of the earliest transcription factors involved in the commitment towards a preosteoclast is PU.1 [1] , which in turn drives the expression of c-fms by osteoclast precursors, the gene encoding for the receptor of macrophage-colony stimulation factor (M-CSF), and of receptor activator of nuclear factor kappa B (RANK) [2] . M-CSF, expressed by osteoblasts mainly as a membrane-bound factor, acts in a paracrine manner by binding to its receptor c-fms, thus stimulating preosteoclast proliferation and differentiation [3] .
The most crucial pathway responsible for osteoclast differentiation is the RANKL/RANK pathway [4, 5] , where the RANK ligand (RANKL) is produced by osteoblasts and, as recently found, osteocytes (see next paragraphs) mainly as a transmembrane cytokine and in smaller quantities as a secreted form (sRANKL), which could come after the proteolytic cleavage of RANKL by metalloproteinases (MMPs). RANK is the receptor for this cytokine, expressed by osteoclast precursors. RANKL binding to its receptor activates the fusion and differentiation of osteoclast precursors into mature osteoclasts by a mechanism that is Nuclear Factor kappa B (NFκB) dependent. In particular, RANKL/RANK interaction recruits TNF receptor activated factor 6 (TRAF6), which in turn activates mitogen-activated protein (MAP) kinases and inhibitor of kappa B (IκB) [6] , eventually leading to the nuclear translocation of the transcription factors c-fos, c-jun, activating transcription factor 2 (ATF2) and NFκB and to the transcriptional expression of osteoclast-specific genes, including cathepsin K CATHK, MMP9, tartrate resistant acid phosphatase (TRAcP) and the calcitonin receptor CTR [7] .
Another transcription factor involved in osteoclast formation is the basic-loop-helix-leucine zipper protein microphthalmia-associated transcription factor (Mitf). Indeed, it has been shown that Mitf-E, whose expression increases during osteoclastogenesis, interacts with PU.1 and enhances the expression of osteoclast-specific genes [8] . The nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1) is another transcriptional factor regulating the expression of osteoclast-specific genes. It is activated by NFATc2 and NFκB, and is subjected to an auto-amplification loop in a process requiring the activation of the calcium/calmodulin-dependent protein calcineurin [6, 9] .
A mature osteoclast is a polarized multinucleated giant cell, with a unique morphology. Its polarization is crucial for the main function of this cell, which is the resorption of the bone matrix [10] . We can therefore identify a bone-facing membrane domain, which includes a "sealing apparatus" that surrounds the portion of the bone to be digested and exhibits a peculiar dot-like adhesion structure. These are called podosomes and are composed of actin-microfilaments, adhesion proteins and actin-binding proteins. They interact with tyrosine kinases and integrin receptors [10] . Podosomes are very dynamic structures, characterized by fast turnover, and they play a crucial role in bone resorption [11, 12] . The other membrane domain of the osteoclast is the basolateral, which faces the vascular stream, and its function is likely related to the process of transcytosis of the degradation products from the resorption lacuna to the extracellular fluids.
The process of bone resorption takes place in the following phases: -Osteoclast adhesion to the bone matrix: this allows the surrounding of the Howship lacunae, that is the part of the bone to be eroded. This adhesion is carried out by podosomes, organized together in peripheral hoops called actin rings [12] . -Acidification of the resorption lacunae: this is the way osteoclasts dissolve hydroxyapatite crystals. In this regard, osteoclasts are equipped with a very efficient machinery, located in the so-called ruffled border, which is basically the bone-facing membrane domain, and composed of an array of membrane evaginations that resemble microvilli [13] . In particular, the V-H+-ATPase proton pump releases protons (H + ) outside the osteoclast and into the Howship lacuna, while the 2Cl − /H + antiporter (also known as Chloride Channel 7) balances the charges. Acidification dissolves the inorganic portion, thus exposing the organic fraction to the attack of lytic enzymes. -Degradation of the organic components: in this phase lysosomal enzymes are released into the resorption lacunae. The most important enzymes involved in this process are cathepsin K [14] , a cysteine protease that mainly degrade collagen I, MMP9 and TRAcP, whose role in this context has yet to be elucidated, despite the volume of literature about this enzyme.
The result of bone erosion is the release from the bone matrix of calcium and growth factors normally stored there, while the fate of the osteoclast is to undergo apoptosis. Indeed, other functions for the osteoclasts have been recognized, which include the ability to regulate osteoblast differentiation and vice versa, as will be described in the following sections. Finally, the role of osteoclasts in the regulation of hematopoietic stem cells (HSCs) by degrading endosteal components, which in turn leads to mobilization of hematopoietic progenitors, has been recently discovered [15] . A correlation between osteoclasts and HSCs is also supported by evidence that treatment with anti-resorptive agents such as bisphopshonates and anti-RANKL antibodies, which reduce the number of osteoclasts, increases the number of HSCs mobilized from the bone marrow [16] .
Osteoblasts: the anabolic cells
Osteoblasts are the cells responsible for depositing new bone. They represent no more than 6% of the total cells in the bone. They deposit bone matrix in their surroundings, eventually becoming buried in their own matrix and becoming osteocytes [17] .
Osteoblasts share a common origin with other cells populating the connective tissues (i.e. fibroblasts, chondrocytes, myoblasts and adipocytes), as they arise from a common pluripotent mesenchymal stem cell (MSC). The differentiation in osteoblasts requires timely programmed steps and the expression of specific genes under the control of activating pathways, which are mainly regulated in a paracrine manner [18] . Two crucial pathways are implicated in osteoblast differentiation: bone morphogenetic proteins (BMPs) [19] and wingless-type (Wnt) signalling [19, 20] .
The first step towards osteoblast differentiation is the commitment of MSCs to the osteo/chondroprogenitor cells, which express the following osteoblast-specific transcription factors: runt-related transcription factor 2 (Runx2), distal-less homeobox 5 (Dlx5) and osterix (Osx). Runx2, also known as core binding factor α1 (cbfα1) and osteoblast specific factor 2 (osf2), is a master gene of osteoblast differentiation, as shown some years ago by the evidence that Runx2-null mice did not develop bone tissue because of the lack of osteoblasts [21, 22] . In agreement with this finding, cleidocranial dysplasia (CCD), an autosomal-dominant disease characterized by abnormal intramembranous ossification, is caused by Runx2 mutations [23] . Runx2 is considered an osteoblast-controlling master gene, as it upregulates osteoblast-specific genes including Collagen 1A1 (COLIA1), Alkaline Phosphatase (ALP), Bone Sialo Protein (BSP) and BGLAP (also known as Ocn, osteocalcin) [24] .
Osterix (OSX), also known as Sp7, is another crucial transcription factor for osteoblast differentiation, promoting transcriptional expression of Satb2 [25] . Experiments performed with Satb2 knock-out (KO) mice as well as haploinsufficiency of SATB2 in humans revealed the involvement of this transcription factor in craniofacial pattern and osteoblast differentiation [26, 27] . It physically interacts with both Runx2 and ATF4, eventually leading to a positive regulation of osteoblast markers [28] .
Finally, the transcription factor Dlx5 promotes osteogenesis under the control of BMPs [29] . Dlx5 is highly expressed in developing skeletons and is also induced during fracture healing [29] .
Moving to the process of osteoblast differentiation, the step coming immediately after the activation of these transcription factors is the commitment of this population towards ALP-positive osteoblast progenitors. These cells are actually now pre-osteoblasts and undergo morphological changes, becoming large, cuboidal cells highly positive for ALP activity and very active in the secretion of bone matrix proteins [17] .
The final stages of osteoblast differentiation are characterized by an increased expression of the bone matrix proteins Ocn, BSP I and II and of collagen type I, all markers featuring a mature osteoblast.
Finally, aging osteoblasts face three different fates: 1) undergo apoptosis; 2) become osteocytes; 3) become bone-lining cells, which are quiescent flat-shaped osteoblasts covering the bone surface, functionally representing the resting phase of the bone remodeling process [17] (see next paragraphs).
The anabolic function of osteoblasts is accomplished by deposition of the organic component of the extracellular matrix, followed by its mineralization. This implies secretion of type I collagen, and non-collagen proteins such as osteopontin, osteonectin, BSP II, Ocn, and proteoglycans (i.e. decorin and biglycan). This new, non-mineralized bone matrix, called osteoid, is then mineralized by the deposition of hydroxyapatite crystals by the secretion of matrix vesicles, extracellular membrane-layered vesicles produced by osteoblasts, chondrocytes and odontoblasts [30] .
As described previously, another important role played by osteoblasts is the paracrine regulation of osteoclast differentiation which, along with systemic regulation, has a pivotal role in bone homeostasis. This is achieved by the above mentioned RANKL/RANK pathway, which includes another player, osteoprotegerin (OPG) [31] . As suggested by the name, OPG inhibits osteoclastogenesis (and therefore bone resorption) by binding to RANKL and avoiding its interaction with RANK. OPG is a soluble factor sharing the same structure as the extracellular domain of RANK and is able to act as a decoy receptor for RANKL. Therefore, osteoclastogenesis relies on a correct RANKL/OPG ratio, both produced by osteoblasts. This underscores even further the crucial role osteoblasts have in regulating bone resorption.
Other paracrine factors produced by osteoblasts that positively influence osteoclast formation are parathyroid hormone-related protein (PTHrP), interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF)-α [7] .
Osteocytes: buried alive
Osteocytes are the most abundant cells in bone ( > 90%) with a characteristic spider-shaped morphology due to the presence of branched cellular processes that build a network of interconnected canaliculi, allowing cell-tocell communication achieved by means of gap junctions [32] . This means that an osteocyte is not just a quiescent osteoblast becoming trapped inside the bone matrix it constructed itself. In fact, this network is crucial for one of the functions of the osteocytes, that is the response of bone to mechanical inputs and the conversion of these stimuli into chemical signals affecting the other cells of the bone [17] .
The differentiation of osteocytes passes through the following four stages [33] : type I preosteocyte (osteoblastic osteocyte); type II preosteocyte (osteoid-osteocyte); type III preosteocyte (young osteocyte); and old osteocyte. These stages are characterized by conspicuous morphological and ultra-structural changes, during which the cell body reduces in size, while cytoplasmic processes start to emerge, and the nucleus/cytoplasm ratio increases. A mature osteocyte loses the typical osteoblast markers and acquires a new set of gene expression, including dentine matrix protein 1 (DMP1) and sclerostin (Sost). The latter is a secreted glycoprotein specifically expressed in osteocytes that inhibits osteoblast differentiation by antagonizing the canonical Wnt pathway [34] . Consistently, bone formation is enhanced in Sost-deficient mice [35] [36] [37] thus indicating Sost as the main negative regulator of osteoblast differentiation and function produced by osteocytes. Therefore, this protein has attracted great interest from a translational point of view by developing anti-Sost antibodies, which proved to be efficacious at counteracting osteoporosis [38] .
It is now well established that osteocytes are more than quiescent cells buried in the bone matrix and that they are responsible for functions which are crucial for the correct bone homeostasis. The classically recognized one is the role as mechanosensors, which is accomplished by translating mechanical stimuli into biochemical signals, which are then transferred to the other cells by means of the cellular processes [39] . This function requires the involvement of a protein complex, composed by the cilium and the cilia-associated proteins PolyCystin 1 and 2 [40] .
Another cell structure actively involved in this mechanosensorial function is the osteocyte cytoskeleton, which is activated by fluid flow, eventually leading to β-catenin stabilization [41] .
The perception of mechanical stimuli results in the ability of osteocytes to influence bone formation and resorption, thus indicating that osteocytes are also regulators of osteoclast and osteoblast functions [17] . With regard to the former cell, osteocyte apoptosis has been shown to be a regulatory event for osteoclast formation. In particular, there is a direct correlation between osteocyte apoptosis induced by microfractures and osteoclast invasion in the site of damage [42] . Moreover, increased production of osteoclast-stimulating factors, including the major regulator RANKL, has been observed in apoptotic osteocytes [43] . Other studies have also demonstrated the ability of osteocytes to increase osteoclast resorption [44] and to resorb surrounding bone when a particularly high amount of calcium is needed by the organism, thus contributing to the regulation of mineral homeostasis [45] .
Physiology of the bone
Dynamicity is a typical characteristic of healthy bone, as during the life of each individual the skeletal tissue undergoes several cycles of renewal, according to a physiological process known as bone remodeling. From this point of view bone is unique, as it is the only tissue that selfdestructs, fulfilling a necessary physiological process for bone homeostasis [46] .
Indeed, a first cycle of bone remodeling, more properly named modeling, happens during childhood. It ensures skeletal growth, under hormonal control, as well as the proper shape of bones. Bone modeling/remodeling strictly relies on a balance between osteogenic functions and bone resorption, which are tightly regulated during bone remodeling. Indeed, while in the latter process bone resorption and formation are tightly coupled and occur in the same place, in bone modeling, resorption and deposition are uncoupled and one can exceed the other [46] . This is particularly true during skeletal growth, when deposition overwhelms resorption [46] .
Thoroughly investigating the bone remodeling process, the following phases can be recognized: -Latent phase: any stimulus including microfracture, mechanical loading changes sensed by the osteocytes and systemic/paracrine factors released in the bone microenvironment activate the so-called lining cells, which usually cover the bone surface rendering it refractory to resorption by osteoclasts. These cells start producing factors that stimulate osteoclast differentiation including monocyte chemoattractant protein-1 (MCP-1), a cytokine secreted in response to PTH, or inflammatory cytokines, such as TNF-α and IL-1β, which attracts osteoclast precursors to the site of bone resorption [47] . -Activation phase: osteoclasts do their job, digesting the bone matrix. This is a quick phase lasting approximately 2-3 weeks in humans. Once osteoclasts resorb the amount of bone they are meant to, they undergo apoptosis, giving way to the reverse cells, which account for the next phase; -Reverse phase: macrophage-like cells, called reverse cells, phagocyte the debris released as a consequence of the bone matrix degradation and produce factors that contribute to the recruitment of osteoblasts in the resorbed area [48] . -Formation phase: this is the longest phase, lasting anywhere between 4 and 6 months. Growth factors released after bone matrix degradation attract osteoblasts, which depose organic matrix (osteoid) and then mineralize it.
All these phases are subjected to finely tuned regulation, which allows a proper balance between bone formation and destruction, eventually leading to correct bone homeostasis. This is achieved not only by means of systemic factors, but also by a tight cross-talk between osteoblasts and osteoclasts [46, 49] .
Clastokines and the paracrine regulation of osteoblasts
Although the ability of osteoblasts to regulate osteoclasts' fate has been well known for many years, little evidence exists about the influence of osteoclasts on osteoblasts'
behavior. An indirect effect is possible, as the degradation of the bone matrix allows the release of several factors stimulating osteoblast differentiation. What has recently emerged is the ability of osteoclasts to directly influence osteoblasts by secreting specific factors described for the first time by Lotinum et al. [50] , the so-called clastokines. Sphingosine-1-phospate (S1P) is induced by treatment with RANKL, eventually leading to a double response: a negative feedback for osteoclast differentiation and the stimulation of osteoblast migration and survival. The net result of this is an increase in bone anabolism [51] . Hepatocyte growth factor (HGF) is another anabolic factor produced by osteoclasts [52] .
Platelet-derived growth factor (PDGF) BB is produced by osteoclasts in response to RANKL treatment and acts as an osteoblastogenesis inhibitor by stimulating osteoblast proliferation and inhibiting their differentiation [53] .
The involvement of TRAcP as a potential clastokine comes from in vivo studies on TRAcP transgenic mice that show a peculiar phenotype, characterized by reduced bone volume but increased bone formation [54] . Moreover it has been recently demonstrated that TRAcP stimulates osteoblast activity [55] .
Other molecules involved in the osteoclast-mediated regulation of osteoblasts with a likely anabolic effect are collagen triple helix repeat-containing 1 (CTHRC1), bone morphogenetic protein 6 (BMP6) and Wnt10b [10] .
Role of growth hormone/insulin-like growth factor-1 in bone metabolism
The effect of growth hormone/insulin-like growth factor-1 (GH/IGF-1) in bone physiology and homeostasis is very complex, and still not entirely elucidated. The GH/IGF-1 axis is one of the major determinants of adult bone mass [56] . GH and IGF-1 are pivotal for bone mass accrual, along with insulin-like growth factor binding protein-3 (IGFBP-3). A positive correlation between BMD and serum concentrations of IGF-1 and IGFBP-3 was observed in healthy men [57] , and rapid decreases in serum IGF-1 levels after menopause might be involved in bone loss in women [58] . GH induces the production of IGF-1 by osteoblasts, but also other factors are involved in IGF-1 regulation. In fact, bone IGF-1 activity can be regulated at multiple levels [59] : PTH and prostaglandin E2 (PGE2) can increase IGF-1 levels [60] . In particular, transient treatment with PTH stimulates collagen synthesis and this effect is mediated by local production of IGF-1 [61] . In vitro, intermittent PTH treatment enhances osteoblast differentiation through an IGF-1 dependent mechanism [62] . The diverse effects on osteoblast differentiation have been shown to depend on the exposure time and to be mediated by different signal transduction pathways [63] . To further understand the complexity of the in vivo effects of the GH/IGF-1/PTH pathway, it is useful to study aging and osteoporosis. In elderly people, bone mass declines [64] mainly due to impaired osteoblast function [65] . Aging is also associated with increased PTH levels and a decrease in GH secretion [66, 67] . Serum IGF-1 concentration has also been reported to be significantly lower in men [57] and women with osteoporosis. It is well established that GH secretion declines with age [67] and IGF-1 declines in serum and bone [68] .
Distal-less homeobox-5 (Dlx5) is a pivotal gene controlling organogenesis, in particular skeletogenesis both for axial, appendicular and craniofacial development. Mutations in this gene cause split-hand/split-foot malformation (SHFM), also referred to as ectodactylia or lobster-claw deformity (OMIM #183600). Dlx5 is proposed to function directly and indirectly as global coordinator of a number of signaling pathways. In particular, it has been shown to be involved in the control of bone formation. In fact this protein is co-recruited with Runx2 to control the expression of Ocn in mouse embryos [69] . Dlx5 could also be directly regulating osteogenesis and/or osteoblast differentiation. This gene is known to activate Ocn [70] Collagen1A1 [71] , secreted phosphoprotein 1 [72] , Runx2 [73] and alkaline phosphatase [74] . Acampora et al. showed that Dlx5 −/− mice exhibit a mild delay in ossification of long bones, in a mechanism that is Runx2-independent [75] . In addition, the gene expression patterns for Ihh (Indian hedgehog)/PTHrP/ parathyroid hormone-related protein-receptor (PTHrP-R) signaling pathway [76] , a key signaling pathway in chondrogenesis, are also blocked or severely impaired. Disruption of these pathways can therefore derive from a delay in osteogenesis that is secondary to impaired cartilage maturation. Wang et al. [77, 78] , demonstrated that a lack of IGF-1 reduced chondrocyte hypertrophy but did not affect proliferation in the growth plate. In addition, after hypophysectomia, administration of IGF-1 to rats increased both chondrocyte proliferation and differentiation [79] . Moreover, Govoni et al. [80] provided in vivo evidence that local chondrocyte-produced IGF-1 is an important regulator of longitudinal growth and bone width in mice, finding a 45% reduction of Dlx5 gene expression in a model of cartilage conditional IGF-1 −/− . PTH, and possibly GH/IGF-1 are also able to activate bone lining cells [81] . In particular, PTH exerts an effect on quiescent lining cells when intermittently administered [82] . In fact, Kim et al. [82] observed the conversion of flat lining osteoblasts in cuboidal mature osteoblasts after PTH administration in mice. PTH is also able to induce the expression of MCP1 in osteoblasts, inducing the recruitment of osteoclast precursors for sustaining bone resorption, both after continuous and intermittent administration [47] .
Beyond bone: bone-derived hormones
During the last few years, bone has emerged as a pivotal integrating organ, acting not only as a passive recipient of other tissues' orders, but also as an active and dynamic regulator of whole-body homeostasis [83, 84] . In particular, several studies have shown that bone has a central role in glucose homeostasis, energy expenditure [85] [86] [87] [88] and even male fertility [89] (Figures 1 and 2 ). The molecule responsible for regulating all of these functions has been identified to be Ocn.
Ocn: just another bone matrix protein?
Ocn is the most abundant noncollagenous protein of the bone matrix [90] . It is composed of 46-50 amino acids, depending on the species, and it is specifically produced by mature osteoblasts. It undergoes several post-translational modifications, including proteolysis of a pre-propeptide and γ-carboxylation of three glutamic residues (at positions 17, 21 and 24) [91] hence the alternative name "bone γ-carboxyglutamate (Gla) protein" (BGLAP). This carboxylation process is regulated by vitamin K [92] and greatly enhances the affinity of Ocn for calcium and hydroxyapatite. This allows the deposition of this protein in the bone matrix during bone formation. At variance, the undercarboxylated (carboxylation only present at residues 21 and 24) form of Ocn has a low affinity for the bone matrix and is readily released into general circulation: in this form, Ocn can efficiently reach distant organs (Figures 1 and 2) . Intriguingly, although Ocn is an osteoblast-specific protein, its role in bone homeostasis has not been completely elucidated. Several independent studies have concluded that Ocn is an osteoblast-osteoclast coupling factor [91] [92] [93] and that a bone matrix deficient in Ocn is poorly resorbed by osteoclasts [94] . In spite of these observations, Ocn KO mice present with high bone mass and The effects of osteocalcin (Ocn) on male fertility. Carboxylated osteocalcin (c-Ocn) is released from the bone matrix and decarboxylated by the low pH in the resorption lacuna. Undercarboxylated osteocalcin (u-Ocn) is then released in the general circulation and targets Leydig cells of the testis. There it binds its only currently known receptor (Gpcr6a) and activates cAMP signaling. This leads to an increase in PKA activity. PKA phosphorylates cAMP response element-binding protein (CREB), which dimerizes and activates several genes involved in testosterone biosynthesis. The resulting increase in testosterone levels influences different aspects of male fertility. have no bone resorption or mineralization defects [95] . Given these findings, an important question arose: Why is this protein so abundant if it is not crucial for bone health? The answer has been found by broadening the view and expanding the field of research from bone homeostasis to whole body homeostasis. Ocn came to be known as the first osteoblast-derived hormone [96] .
As we stated in the previous paragraph, Ocn is mainly present in the bone matrix in carboxylated form [96] . In this state, its affinity for the bone matrix is high, which causes it not to be efficiently released into general circulation. Nevertheless most of the Ocn found in sera is present as carboxylated-Ocn (c-Ocn) in both mice and humans in physiological conditions [97] . Of particular interest, a small fraction of Ocn is found in an undercarboxylated form in the general circulation. This raised many questions: How is Ocn decarboxylated? Why? By which cell or under which condition? Indeed, the only known way to decarboxylate γ-carboxyglutamic acid in proteins is by exposing it to an acidic environment [98] . Furthermore, the undercarboxylated form of Ocn has been shown to be the one with biological activity in other organs, as opposed to the c-Ocn, which holds no detectable effect [88] . At this point the involvement of the osteoclast became apparent. As already described, osteoclasts are able to create a tightly sealed, acidified (pH 4.5) environment in order to dissolve the inorganic matrix during bone resorption [10] . The acidity created by the osteoclast in resorption lacuna is indeed capable of decarboxylating Ocn [88] , thus rendering it active.
This complex mechanism of deposition, liberation and activation requires a concerted action between osteoblasts and osteoclasts, thus rendering Ocn activity finely controllable in different points (Figure 1 ). All of these can be exploited by different exogenous stimuli to induce or repress Ocn's activity.
Bone and pancreas: a healthy relationship
The first important function that has been ascribed to bone as an endocrine organ is control over glucose metabolism [99] . The hypothesis came from a few simple observations mainly based on three genetically engineered mouse models: 1) Ocn −/− mouse; 2) Esp −/− mouse and 3) Esp obs −/− mouse, the latter being a conditional KO of Esp, as it is deleted only in the osteoblast lineage. The Esp (embryonic stem-cell phosphatase) gene encodes for a rather elusive protein tyrosine phosphatase (OST-PTP, Osteotesticular protein tyrosine phosphatase) without any known targets that is expressed by embryonic stem cells during development, and only by Sertoli cells and osteoblasts in postnatal life [100] . Both Esp −/− and Esp obs −/− mice present with perinatal lethality due to severe hypoglycemia, thus strongly suggesting that osteoblasts are capable of inducing radical changes in glucose homeostasis, and that Esp is a cornerstone in this peculiar mechanism [100] . Indeed, Esp expression in osteoblasts has been shown to inhibit expression and secretion of insulin by pancreatic β-cells, to reduce insulin sensitivity in muscle, adipose tissue and the liver, and to decrease energy expenditure [99] . The crucial observation was that Esp obs −/− mice had a phenotype that was in good substance opposite to that of Ocn −/− mouse, as far as energy metabolism goes [99] , thus suggesting that Esp and Ocn were two members of the same pathway, cooperating in the regulation of pancreatic β-cells proliferation, insulin sensitivity and, consequentially glucose homeostasis. Of note, Ocn expression was unchanged in Esp obs −/− mice, suggesting that the control of Esp over Ocn is achieved post-transcriptionally or posttranslationally [99] . Importantly, deleting an allele of Ocn in Esp −/− mice (Esp −/− Ocn
) rescued the energy metabolism phenotype. Therefore Esp −/− mouse can also be considered as an Ocn gain of function model. Intravenous administration of undercarboxylated, but not c-Ocn was able to restore the energy metabolism of the Ocn −/− mouse, further suggesting that the undercarboxylated form of Ocn is the active one [99] .
But insulin was not the entire story: adiponectin, a crucial factor involved in insulin resistance [100] also seemed to be influenced by Ocn [101] (Figure 1 ). In fact, administration of undercarboxylated-Ocn (u-Ocn) in vitro or in vivo (by osmotic pump implant) was able to significantly increase adiponectin gene expression in primary white and brown adipocytes or white adipose tissue, respectively [101] . It is also interesting to note that the amount of Ocn required to influence adipocytes was two orders of magnitude higher than what was needed to influence β-cells, suggesting that this versatile hormone can in fact act on more than one tissue at different concentrations.
Of course, it takes two to tango, and the relationship between bone and pancreatic β-cells goes both ways: not only does Ocn influence insulin release and β-cell proliferation, but also insulin is able to influence osteoblasts (directly) and osteoclasts (through osteoblasts) by working as an anabolic agent for bone and promoting bone remodeling [88, 101] . This creates a putative feed-forward loop where osteoblasts stimulate β-cells to proliferate and secrete insulin, which in turn stimulates osteoblast differentiation and downregulates the decoy receptor for RANKL, OPG, eventually leading to an increased osteoclast function, and thus an increase in the liberation of u-Ocn, which restarts the loop (Figure 1) [88, 101] . In fact, osteoblasts have a functional insulin receptor (INSr), and INSr obs −/− mice have both skeletal abnormalities and energy metabolism defects [88, 101] . As it turns out, INSr obs −/− mice actually have an energy metabolism phenotype that closely mimics the one from the Ocn −/− mouse [88, 101] , and therefore is opposite to the one found in Esp −/− mice. In all insulin-sensitive tissues INSr dimerizes and auto-phosphorylates after binding insulin, and the osteoblast is no exception to this rule [102] . Being OST-PTP a protein tyrosine phosphatase, it was logical to think of an interaction between this protein and INSr. In fact, OST-PTP seems able to dephosphorylate INSr after it binds insulin, hampering its action and blocking the insulin-signaling pathway in osteoblasts [88, 101] (Figure 1) .
Ocn was indeed acting as a hormone, and of course, depending on the target tissue, hormones can exert different functions: Ocn does not escape this rule.
Testis: fertile soil for Ocn
It is well known that skeletal metabolism is affected by sexual hormones, so that the drastic reduction of estrogen production at menopause leads to the onset of osteoporosis, as estrogen is anabolic for bone, by both impairing osteoclast formation and function and stimulating osteoblast survival [103] [104] [105] . Also men's bone health is influenced by gonadotropins: testosterone acts on osteoblasts by decreasing their apoptosis, and increasing proliferation and differentiation, while concomitantly reducing OPG expression [74] .
Before the discovery of Ocn, few could imagine that bone was talking back to the gonads. The first evidence of this came from ex vivo assays. A factor secreted by osteoblasts, but not other mesoderm-derived cells, could increase testosterone production in primary Leydig cells [89] .
The evidence that this factor was indeed Ocn came from both in vitro and in vivo experiments. In fact, conditioned medium (CM) from Ocn −/− osteoblasts did not have any effect on testosterone production in Leydig cells [89] , while both WT (wild-type) CM and u-Ocn induced testosterone production in a dose-dependent fashion (Figure 2) [89] . A very elegant in vivo experiment from the same article, showed how in vivo osteoblast ablation by diphtheria toxin (DTA obs mice) hampered testis development and reduced testosterone levels. These effects were rescued by in vivo treatment of these mice with u-Ocn [106] . To strengthen these results, gonadal functions were evaluated in Ocn −/− (an obvious model of Ocn loss of function) and Esp −/− (a model for Ocn gain of function, as mentioned in the previous paragraph) mice. Ocndeficient mice showed a decrease in testes, epidydimedes and seminal vesicles weights, while the Esp conditional KO in osteoblasts showed opposite results. Sperm-count was halved in Ocn −/− compared to WT littermates, while it increased by a third in Esp obs −/− . Moreover, Leydig cells seemed unable to mature properly without Ocn, leading to lower testosterone levels in the Ocn −/− model. The opposite was seen in Esp obs −/− mice [89] . It is interesting to note how Ocn does not seem to affect female fertility, which is consistent with the fact that its receptor (Gpcr6a, OcnR) is expressed in male, but not female gonads [89] . The mechanism of action through which Ocn exerts its functions has been found to be CREB (cAMP response element-binding protein)-dependent. The proposed mechanism of action, demonstrated by in vitro and in vivo approaches, is the following: 1) Ocn binds OcnR, which activates cAMP production; 2) PKA phosphorylates CREB; 3) CREB activates key enzymes of testosterone biosynthesis (StAR, steroidogenic acute regulatory protein, 3β-HSD, 3β-Hydroxysteroid dehydrogenase/Δ 5−4 isomerase and others) ( Figure 2 ) [89] . This ground-breaking discovery was also confirmed in humans by correlative observations of testosterone and Ocn levels during developmental age, especially puberty. In fact, Ocn levels are significantly associated with testosterone levels during this age in young men, but not in young women [106] .
The link between bone and brain
We have been through a series of unexpected regulatory mechanisms mediated by an osteoblast-derived hormone, Ocn, but perhaps the most interesting effect it mediates is about brain development and efficiency [107] . Many brain-derived signals have been shown to regulate bone accrual and remodeling, especially through the sympathetic nervous system that is able to regulate both osteoblasts and osteoclasts at the same time [89, 108, 109] . What is most surprising though, is that bone can also influence cognitive functions, again through Ocn [107] . The study showing this regulation started because the Ocn −/− mice showed unusual passiveness and unwillingness to deambulate, as they quantified using the open field test [107] . Intriguingly, no difference was detected in OcnR −/− mice, suggesting that the mechanism is not mediated by this G-protein coupled receptor. The studies have been conducted on female Ocn −/− mice, which have no difference in sex steroid hormones, and this may be a possible confounding factor. The use of OcnR −/− mice also rules out the possibility the differences are due to a metabolic phenotype because these mice are practically identical to the Ocn −/− mice, as far as metabolism goes [107] . Several differences in the behavioral phenotype of Ocn −/− have been detected: anxiety-like behavior, depression, lower spatial learning and memory [107] . This impressive array of behavioral phenotypes prompted the investigators to look more deeply into the function that Ocn may exert on the brain. As it turned out, many neurotransmitters are influenced by the lack of Ocn: GABA (γ-amino-butyric-acid), the most well-characterized inhibitory neurotransmitter in the CNS was higher in all areas of the Ocn −/− mice brain. In contrast, the norepinephrine and serotonin content were significantly decreased in the brainstem, while dopamine was lower in the midbrain, cortex and striatum of the Ocn −/− mice compared to WT and OcnR −/− [107] . These findings were justified by changes in the gene expression levels of enzymes necessary for the synthesis of these neurotransmitters [107] . Given these powerful effects on the neural phenotype and neurotransmitter content in the Ocn −/− mice, the investigators focused on the mechanism through which Ocn signals to the brain. The first important finding is that u-Ocn crosses the blood-brain barrier, accumulating in the brain stem, thalamus and hypothalamus of Ocn −/− mice when administered subcutaneously [107] . After this finding, they showed that Ocn binds neurons of the midbrain (ventral tegmental area, a nucleus presenting numeorus dopaminergic neurons), brain stem (dorsal and median raphe nuclei, rich with serotoninergic neurons) and the CA3 region (cornus ammonis region 3) of the hippocampus [107] . After proving that treating adult Ocn −/− mice with Ocn could normalize the expression of most of the enzymes for the production of neurotransmitters, they found that this treatment could rescue most behavioral phenotypes, but could only partially rescue spatial learning and memory. This difference in the efficacy of the rescue was found to be an effect on brain development: Ocn −/− mice have ⅓ less dentate gyrus area, compared to WT. In agreement with this, postnatal ablation (3 months-of-age) of Ocn expression by a tamoxifen-inducible model induced all of the phenotypes found in Ocn −/− mice, but the spatial learning and memory effect were less severe compared to the embrional KO, and no difference was detected in the dentate gyrus area [107] . This prompted the researchers to evaluate the effect that Ocn may have on brain development.
Ocn begins to be expressed around E16.5 during embryonic life, as they demonstrate by in situ hybridization and by using Ocn-mCherry mice. The interesting part is that Ocn is detectable in the foetus at E14.5, before the mRNA expressions starts. How can this happen? The only logical explanation for this event is that Ocn crosses the placental barrier, as it does the blood-brain barrier, and enters the circulation of the pups [107] . Intriguingly, only the undercarboxylated form of Ocn was able to cross the placenta [107] . Embryos of Ocn ) were analyzed for Ocn-protein content in different developmental stages, and postnatally. What emerges is that pups carried by Ocn-deficient mothers undergo different degrees of neural development defects, depending on the genotype of the mother, even if they are WT [107] . Probably the most relevant effect deriving from the lack of maternal Ocn during embryonic development is a significantly higher (two-fold compared to WT mother with WT pup) apoptosis in hippocampal neurons, which is partially rescued using Ocn +/− mother with Ocn −/− pups. This explains the spatial learning and memory phenotype, and why this phenotype is milder in postnatal ablation of the gene [107] .
This has led to the speculation that poor bone health in human mothers could lead to neurodegenerative conditions in the children, a hypothesis that is currently being tested by correlative studies.
Bone and kidney: the role of fibroblast growth factor 23
Fibroblast growth factor 23 (FGF23) is widely expressed in different tissues, including the ventrolateral thalamic nucleus, thymus, lymph nodes, and last but not least, bone, where it is mainly produced by osteocytes [110, 111] . FGF23 is a 32-kDa protein acting as a phosphaturic factor and inhibitor of 1-α-hydroxylase activity in the kidneys [112, 113] , making it functionally unique among FGFs. Most of our knowledge of FGF23 involvement in Pi metabolism comes from the study of diseases with autosomal dominant hypophosphatemic rickets (ADHR) [113] , which carry missense mutations in the FGF23 gene that confer resistance to proteolytic degradation of the FGF23 protein [114] eventually leading to higher serum FGF23 levels. Other diseases linked to FGF23 abnormalities are X-linked hypophosphatemic rickets (XLH), autosomal recessive hypophosphatemic rickets (ARHR) and tumorinduced osteomalacia (TIO).
FGF23 mainly targets the kidneys (Figure 3 ), in order to guarantee the correct Pi homeostasis [115] . Pi reabsorption in the kidneys normally is driven by two primary transport proteins, the type II sodium-phosphate co-transporters NPT2a and NPT2c, expressed in the apical membrane of the proximal tubule. Renal Pi-wasting occurs after FGF23 High levels of Pi and vitamin D 3 stimulate osteocytes to produce FGF23. This protein is released in the general circulation and targets parathyroid glands, where it could stimulate an increase in parathyroid hormone (PTH) levels. FGF23 signaling in the kidneys stimulates Pi-wasting and decreases vitamin D 3 production, while contemporarily stimulating its catabolism. The resulting decrease in Pi levels works as negative feedback for FGF23 production by the osteocyte. This mechanism allows fine regulation of circulating Pi levels. signals to the kidneys, through the downregulation of both Npt2a and Npt2c [110] . Normally, hypophosphatemia is a strong inducer of serum 1,25(OH) 2 D 3 , the active form of vitamin D 3, also called calcitriol. However, despite severe hypophosphatemia, TIO, ADHR, XLH, and ARHR patients present with low or normal levels of 1,25(OH) 2 D 3 . The answer to this apparent paradox has been found by in vivo studies on mice. In fact, administration of FGF23 reduces the expression of the 1-α-hydroxylase (the enzyme responsible for the synthesis of 1,25(OH) 2 D 3 ) and increases the 24-hydroxylase enzyme that inactivates 1,25(OH) 2 D 3 [112] . Consistently, in ADHR, XLH, TIO and ARHR patients FGF23 levels are high and the chronic hypophosphatemia is due to this factor [116] .
FGF23 also targets the parathyroid gland (Figure 3 ). FGFR and Klotho (a FGF23 co-receptor necessary for the full activation of the pathway) are co-expressed in parathyroid glands [115, 117] . Furthermore, elevated FGF23 levels in animal models lead to high PTH levels. However, further studies are needed to define the effects of FGF23 on PTH production and secretion and parathyroid cell proliferation.
FGFs interact with one of four FGF receptors (FGFR) that belong to type I transmembrane phosphotyrosine kinase receptors. FGF23 usually interacts with FGFR types 1c, 3c, and 4c [118, 119] . The ligand-receptor interaction also requires the binding to the co-receptor α-Klotho (α-KL) [120] , a single-pass transmembrane protein. The FGF-FGFR-α-KL complex is required for the complete receptor activation [121] . Membrane-bound KL (mKL) is a 130-kD single-pass transmembrane protein formed by a large extracellular domain and a very short (10 residues) intracellular domain without signaling activity [117] . The mKL protein can be cleaved, giving rise to a circulating form of αKL. A secreted isoform of KL (sKL) is also produced (which is similar to the cleaved form of mKL) as a result of a splicing variant, which does not contain the transmembrane domain [117] .
FGF23 activity and expression are regulated by local and systemic bone-derived factors, both transcriptionally and post-translationally [111] . Serum FGF23 levels are regulated by Pi [116] and 1,25(OH) 2 D 3 [111] as well as by the osteocytic cell-surface endopeptidase Phex (phosphate regulating endopeptidase homolog, X-linked) that co-localizes with FGF23 in osteocytes [111] , DMP1, a SIBLING extracellular matrix protein [122, 123] and matrix extracellular phosphoglycoprotein (MEPE) [96] . FGF23 levels are increased by Pi [116] , while administration of 1,25(OH) 2 D 3 reduces circulating FGF23 [111, 116] . Renal failure also increase FGF23 levels [116, 124, 125] , with direct correlation with the degree of hyperphosphatemia [125] . Regarding systemic factors, only 1,25(OH) 2 D 3 has been shown to stimulate directly increases in FGF23 promoter activity in osteoblasts through a vitamin D responsive element.
With regard to the afore-mentioned factors expressed by osteocytes that regulate FGF23, it has been demonstrated that the targeted deletion of DMP1 in mouse model increases FGF23 expression in osteocytes, leading to increased circulating levels [122] . In contrast, phosphaturia occurs after MEPE administration, possibly by increasing FGF23 levels [126] [127] [128] . Inactivating mutations of Phex, also result in increased transcription of FGF23 and elevated circulating levels [111] . More recently, a chondrocyte inhibitor of FGF23 transcription was reported, but the molecular identity of this putative factor has not been defined [129] .
Other bone-derived hormones
Recently, the role of the class II histone deacetylase 4 (HDAC4) has been investigated in the context of the osteoblasts [130] . HDAC4 accumulates in osteoblasts' nuclei , associates with ATF4 and is able to increase ATF4-dependent RANKL expression in osteoblasts following sympathetic stimulation [130] . In a recent work by Makinistoglu and Karsenty [131] , HDAC4 has also been demonstrated to control Ocn expression, therefore working as an integrator of extracellular stimuli, such as sympathetic tone, that regulates Ocn expression. But this is not the end of the story: the energy metabolism of HDAC4 obs −/− mice is similar to that of Ocn −/− mice, yet not identical [131] . The most relevant change in energy metabolism was that HDAC4 obs−/− mice have a significantly lower food intake, and consequently a lower body weight, compared to WT. This variable was not affected in Ocn −/− mice. The changes in food intake were not due to changes in leptin levels [131] .
This could mean that Ocn is not the only bone-derived factor influencing energy metabolism, and therefore, it seems logical to think of a novel osteoblast-derived hormone, controlling different aspects of energy metabolism, and possibly other functions, in concert with Ocn and/or maybe independently from it.
Conclusions
Bone is a fascinating tissue. Every time we think almost everything has been said about bone biology, a new crucial player enters the game. This has been the case for recent evidences showing that bone also has an endocrine role, in addition to its classically recognized functions.
In this review we wanted to show how interesting and important bone is in a context that transcends bone biology, to lay its feet in whole body homeostasis, reproduction and even cognitive functions. If we stop and think about bone biology, we may find ourselves wondering why a tissue would periodically destroy itself just to re-build what was destroyed shortly after. This is a terribly energyexpensive process that has always been justified with a simple "to keep mechanical properties high". Today, thanks to many brilliant researchers, we have realized that this is not the end of the story: hormones and growth factors are buried in the bone matrix, and the osteoclasts are able to liberate (and sometimes activate) them in the general circulation.
Osteocytes are maybe the best example of how misled we have been the past few years. We thought they were just "quiescent osteoblasts", ending up buried in their own matrix and then just living the rest of their lives in peace. Nothing could be more wrong. They are extremely dynamic cells, responding to mechanical stimuli, capable of resorbing bone when needed and even replace resorbed bone with new bone during lactation. Not only that, they are also endocrine cells, contributing to Pi homeostasis, and with their long-reaching processes they manage to create an incredible network, much like a "bone nervous system", where the osteocytes correspond to neurons.
Understanding how bone communicates with other organs might enable us to understand pathologies we could not, and possibly to identify new therapeutic targets based on these communication mechanisms.
In conclusion, our vision of bone biology has deeply changed in the last few decades. This should prompt us to study and improve our knowledge about this amazing tissue, with the ultimate goal of helping people affected by pathologies we never imagined to be linked to bone.
